Table 3 Overall response rate

From: A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated

 

Number of Patients (%)

 

Paclitaxel+cisplatin (n=70)

Vinorelbine+cisplatin (n=70)

Overall response

27 (38.6)

27 (38.6)

 Complete response

1 (1.4)

0

 Partial response

26 (37.2)

27 (38.6)

Stable disease

25 (35.7)

32 (45.7)

Progressive disease

14 (20)

7 (10)

Unevaluable

4 (5.7)

4 (5.7)

  1. The 95% confidence interval of the overall response rate was the same in both arms: 29.3–47.9%.
Back to article page